DOI: https://doi.org/10.15587/2313-8416.2014.31916

Прогнозирование летального исхода у больных острым коронарным синдромом в ближайший и отдаленный периоды

Николай Павлович Копица, Ирина Руслановна Вишневская

Аннотация


В настоящее время в лечении острого коронарного синдрома  подчеркивается важность ранней стратификации риска с целью выявления наиболее «уязвимых» пациентов. Для повышения прогностической значимости общепринятой шкалы риска GRACE предложено использование нового биомаркера GDF-15. Полученные данные свидетельствуют об эффективности разработанной мальтифакторной модели с включением нового биомаркера.


Ключевые слова


острый коронарный синдром; биомаркеры; прогноз; стратификация; риск; шкалы; инфаркт миокарда; стресс; воспаление; цитокины

Полный текст:

PDF

Литература


Lange, R. A. (2013). Can You Predict What Happens When EuroSCORE Weds Biomarker?. Journal of the American College of Cardiology, 61 (6), 682–684. doi: 10.1016/j.jacc.2012.11.028

Bootcov, M. R. (1997). MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the tgf-b superfamily. Proceedings of the National Academy of Sciences, 94 (21), 11514–11519. doi: 10.1073/pnas.94.21.11514

Wollert, K. C., Kempf, T., Peter, T., Olofsson, S., James, S., Johnston, N. et. al. (2007). Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome. Circulation, 115, 962–971. doi: 10.1161/circulationaha.106.650846

Xu, J. (2006). GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circulation Research, 98 (3), 342–350. doi: 10.1161/01.res.0000202804.84885.d0

Bonaca, M. P., Morrow, D. A., Braunwald, E. (2011). Growth Differentiation Factor-15 And Risk Of Recurrent Events In Patients Stabilized After Acute Coronary Syndrome: Observations From PROVE IT-TIMI 22. Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 203-210. doi: 10.1161/atvbaha.110.213512

Kempf, T., Sinning, J. M., Quint, A., Bickel, C., Sinning, C. et al. (2009). Growth differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circulation: Cardiovascular Genetics, 2 (3), 286–292. doi: 10.1161/circgenetics.108.824870

Anand, I. S., Kempf, T., Rector, T. S., Tapken, H., Allhoff, T. et al. (2010). Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation, 122, 1387–1395. doi: 10.1161/circulationaha.109.928846

Xu, J. (2006). Gdf15/mic-1 functions as a protective and antihypertrophic factor released from the myocardium in association with smad protein activation. Circulation Research, 98 (3), 342–350. doi: 10.1161/01.res.0000202804.84885.d0

Kempf, T., Zarbock, A, Widera, C, Butz, S. et al. (2011). GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nature Medicine, 17 (5), 581–588. doi: 10.1038/nm.2354


Пристатейная библиография ГОСТ


1. Lange, R. A. Can You Predict What Happens When EuroSCORE Weds Biomarker? [Text] / A. R. Lange // Journal of the American College of Cardiology. – 2013. – Vol. 61, Issue 6. – P. 682–684. doi: 10.1016/j.jacc.2012.11.028 

2. Bootcov, M. R. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the tgf-b superfamily [Text] / M. R. Bootcov, A. R. Bauskin, S. M. Valenzuela, A. G. Moore, et. Al. // Proceedings of the National Academy of Sciences. – 1997. – Vol. 94, Issue 21. – P. 11514–11519. doi: 10.1073/pnas.94.21.11514 

3. Wollert, K. C. Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome [Text] / K. C. Wollert, T. Kempf, T. Peter, S. Olofsson, S. James, N. Johnston et. al. // Circulation. – 2007. – Vol. 115. – P. 962–971. doi: 10.1161/circulationaha.106.650846 

4. Xu, J. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation [Text] / J. Xu // Circulation Research. – 2006. – Vol. 98, Issue 3. – P. 342–350. doi: 10.1161/01.res.0000202804.84885.d0 

5. Bonaca, M. P. Growth Differentiation Factor-15 And Risk Of Recurrent Events In Patients Stabilized After Acute Coronary Syndrome: Observations From PROVE IT-TIMI 22 [Text] / M. P. Bonaca, D. A. Morrow, E. Braunwald // Arteriosclerosis, Thrombosis, and Vascular Biology. – 2011. – Vol. 31, Issue 1. – P. 203–210. doi: 10.1161/atvbaha.110.213512 

6. Kempf, T. Growth differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study [Text] / T. Kempf, J. M. Sinning, A. Quint, C. Bickel, C. Sinning, et al. // Circulation: Cardiovascular Genetics. – 2009. – Vol. 2, Issue 3. – P. 286–292. doi: 10.1161/circgenetics.108.824870 

7. Anand, I. S. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial [Text] / I. S. Anand, T. Kempf, T. S. Rector, H. Tapken, T. Allhoff, et al. // Circulation. – 2010. – Vol. 122, Issue 14. – P. 1387–1395. doi: 10.1161/circulationaha.109.928846 

8. Xu, J. Gdf15/mic-1 functions as a protective and antihypertrophic factor released from the myocardium in association with smad protein activation [Text] / J. Xu // Circulation Research. – 2006. – Vol. 98, Issue 3. – P. 342–350. doi: 10.1161/01.res.0000202804.84885.d0 

9. Kempf, T. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice [Text] / T. Kempf, A. Zarbock, C. Widera, S. Butz et. al. // Nature Medicine. – 2011. – Vol. 17, Issue 5. – P. 581–588. doi: 10.1038/nm.2354 







Copyright (c) 2014 Николай Павлович Копица, Ирина Руслановна Вишневская

Creative Commons License
Эта работа лицензирована Creative Commons Attribution 4.0 International License.

ISSN 2313-8416 (Online), ISSN 2313-6286 (Print)